Physicians should be aware when developing a treatment plan that patients' lack of trust in the medical profession can affect their willingness to seek medical treatment and comply with the treatment.
A physician explains that the sale of nonprescription cosmeceuticals from a dermatology office should be done in a manner that is educational but non-threatening to patients.
A physician and a lawyer argue against a dermatology clinic switching from a small, reliable pathology lab to a large-scale pathology lab in order to receive volume discounts and increase profit.
A physician responds to a previous article about the differences between using a commercial laboratory and a smaller hospital or pathology group lab for dermatological tests.
A physician discusses how medical students should handle an interaction with a patient who has not yet received information from the physician regarding test results and their implications.
Richard L. Kravitz, MD, MSPH and Jodi Halpern, MD, PhD
Patients have a responsibility to discerningly present the drug information they receive from direct-to-consumer advertising and to be active partners with their physician in making health care decisions.
Physicians are cautioned that the two obstacles to reforming post-marketing clinical trials are the FDA's reluctance to revisit past approvals and its inability to enforce pharmaceutical companies' commitment to conduct Phase IV trials.
Dr Noah Boton joins Ethics Talk to discuss his article, coauthored with Dr Jeffrey Larnard: “When Should Patients at the End of Life Get Antimicrobials?”